Obesity Expert Calls for FDA Crackdown on Compounded GLP-1s

An obesity expert operating a telemedicine practice has called for the U.S. Food and Drug Administration (FDA) to enforce regulations against online sellers and prescribers who exploit compounding laws for GLP-1 drugs. The expert, who has never prescribed a compounded GLP-1 despite treating obesity extensively via video, argues that legitimate telemedicine should not cut corners. The core issue is the proliferation of compounded GLP-1 versions marketed as lower-cost, readily available alternatives to FDA-approved medications, which poses significant risks to patient safety and physician licensure. Compounded drugs bypass the rigorous inspections and reviews that commercially manufactured medicines undergo. While some compounding pharmacies adhere to high standards, including issuing certificates of analysis and conducting third-party testing, others do not. Patients ordering these compounded versions online often lack the transparency to discern the quality or exact contents of what they are injecting. This lack of oversight makes it difficult for physicians to diagnose and manage potential side effects, as they cannot be certain whether adverse reactions stem from the active drug, its dosage, or unlisted additives. Earlier this year, the FDA issued warning letters to 30 telehealth companies for blurring the lines between approved and compounded GLP-1s in their advertising. However, the expert contends that such admonishments are insufficient to curb the market's growth, which has surged alongside demand for GLP-1s. The expert proposes that the FDA issue clear guidance stating that cost is not a valid medical justification for compounding a drug, that a compounded GLP-1 is not an equivalent substitute for an approved version, and that prescribing compounded versions without genuine medical necessity endangers patients and jeopardizes physicians' licenses. The expert also directly addresses prescribers, urging them to cease prescribing compounded GLP-1s if they cannot articulate a specific medical reason for their use beyond cost or availability. The practice of compounding involves mixing, combining, or altering ingredients to create a medication tailored to an individual patient's needs, typically when an FDA-approved drug is not available or suitable. However, the surge in demand for weight-loss drugs like semaglutide and tirzepatide has led to a significant increase in compounding, with some pharmacies creating large batches for widespread distribution, a practice that deviates from the original intent of personalized compounding and raises safety concerns. The expert emphasizes that without robust oversight, the contents of the vial can be unpredictable, potentially containing incorrect dosages or harmful contaminants, thereby undermining the trust and efficacy expected from medical treatments.